The South Korean won is up 0.29%, and the Japanese yen gains 0.19%.
The South Korean won is up 0.29%, and the Japanese yen gains 0.19%. The Chinese yuan is little changed.
A chronological text record of the AI Market Commentator: important releases, breaking developments, market reactions and concise context for the trading day.
The South Korean won is up 0.29%, and the Japanese yen gains 0.19%. The Chinese yuan is little changed.
US index futures: S and P futures is up 0.03 percent, Nasdaq futures is up 0.16 percent, Dow futures is down 0.14 percent and Russell futures is down 0.12 percent.
Cognizant and Benchling were selected as partners to accelerate Kyowa Kirin’s R&D.
US gasoline futures are holding near a two-week high at $3.18 per gallon. This follows slower crude shipments through the Strait of Hormuz, stalled US-Iran talks, and Russian fuel disruptions.
US index futures: S and P futures is up 0.07 percent, Nasdaq futures is up 0.23 percent, Dow futures is down 0.09 percent and Russell futures is down 0.07 percent.
Australian stocks are down 0.3% to 9,089 in early trade, extending losses for a fourth straight session to a two-week low. Banks and retailers are leading the declines.
Breaking. China's central bank injects 565.5 billion yuan via overnight reverse repos.
Breaking. China’s central bank reports 7-day reverse repo volume hits zero Monday, citing primary dealer demand as the stated driver.
China has set the yuan midpoint at its strongest level since February 8, 2023.
US index futures: S and P futures is up 0.08 percent, Nasdaq futures is up 0.26 percent, Dow futures is down 0.06 percent and Russell futures is down 0.05 percent.
US index futures: S and P futures is up 0.05 percent, Nasdaq futures is up 0.17 percent, Dow futures is down 0.06 percent and Russell futures is down 0.05 percent.
US index futures: S and P futures is up 0.11 percent, Nasdaq futures is up 0.26 percent, Dow futures is up 0.03 percent and Russell futures is up 0.03 percent.
Japan's Q2 GDP deflator rose 2.6% year-on-year. Separately, HUTCHMED reports that ORPATHYS plus TAGRISSO showed statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after TAGRISSO progression.
SquawkNews LiveCast Briefs are informational market commentary, not investment advice. Facts may be corrected as verified information changes.